On day 18 post MC-38 tumor challenge, the percentage of CD8+ and CD4+ T cells within the circulating leukocytes in blood and spleen increased after PDOX treatment compared with no treatment and anti-PD-L1 treatment (Figure S1E). The gene discussed is CD8A; the disease is neoplasm.